Catheter Precision (NYSE: VTAK) records 49.5% shareholder turnout

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

8-K

Rhea-AI Filing Summary

Catheter Precision, Inc. reported the results of a Special Meeting of stockholders held on April 15, 2026. Of the 2,357,127 shares of common stock outstanding as of March 9, 2026, 1,165,698 shares were represented in person or by proxy, representing approximately 49.5% of shares entitled to vote.

Stockholders considered six proposals described in the company’s definitive proxy statement filed on March 23, 2026. The company disclosed detailed vote tallies for each proposal, including votes for, votes against, abstentions, and broker non-votes.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding: 2,357,127 shares Shares represented: 1,165,698 shares Proposal vote example 1: 690,693 for / 85,706 against +2 more

5 metrics

Shares outstanding 2,357,127 shares Common stock outstanding as of March 9, 2026

Shares represented 1,165,698 shares Represented at Special Meeting; approximately 49.5% turnout

Proposal vote example 1 690,693 for / 85,706 against One proposal’s votes, plus 9,908 abstentions and 379,391 broker non-votes

Proposal vote example 2 991,353 for / 136,304 against Another proposal, plus 38,041 abstentions and no broker non-votes

Number of proposals 6 proposals Considered at the April 15, 2026 Special Meeting

Key Terms

Special Meeting, definitive proxy statement, Schedule 14A, Broker Non-Votes, +1 more

5 terms

Special Meeting financial

"On April 15, 2026, the Company held a Special Meeting of stockholders"

A special meeting is a shareholder gathering called outside the regular annual meeting to decide on urgent or specific corporate matters, such as mergers, major asset sales, changes to the board, or shareholder proposals. It matters to investors because decisions made there can quickly alter a company’s strategy, ownership or value—like a sudden boardroom decision that changes the game—so shareholders may need to vote, adjust holdings, or reassess risk based on the outcome.

definitive proxy statement regulatory

"which are described in more detail in the Company’s definitive proxy statement on Schedule 14A"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

Schedule 14A regulatory

"definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 23, 2026"

Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.

Broker Non-Votes financial

"Votes For | | Votes Against | Abstentions | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

04/15/2026 - 04:16 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 15, 2026

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38677		38-3661826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

(973) 691-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VTAK	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On April 15, 2026, the Company held a Special Meeting of stockholders at which, of the 2,357,127 shares of the Company’s common stock outstanding as of March 9, 2026, the record date for the Annual Meeting, 1,165,698 shares of common stock were represented, either in person or by proxy, constituting, of the shares entitled to vote, approximately 49.5% of the outstanding shares of common stock.

At the Annual Meeting, the Company’s stockholders considered six proposals, which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 23, 2026. The matters voted on at the Special Meeting and the votes cast with respect to each such matter are set forth below:

Proposal No. 1: To approve the issuance of shares of the Company's common stock underlying shares of the Company's Series C-1 convertible preferred stock, Series C-2 convertible preferred stock, Series C-3 convertible preferred stock and Series C-4 convertible preferred stock. Proposal No. 1 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
690,693		85,706	9,908	379,391

Proposal No. 2: To approve the issuance of shares of the Company's common stock underlying shares of the Company's Series D convertible preferred stock. Proposal No. 2 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
690,581		88,818	9,908	376,391

Proposal No. 3: To approve the issuance of shares of the Company's common stock underlying shares of the Company's Series J convertible preferred stock. Proposal No. 3 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
690,667		88,732	9,908	376,391

Proposal No. 4: To approve the issuance of additional shares of the Company's common stock as a result of the reduction of the conversion price of the Company's currently outstanding Series B convertible preferred stock. Proposal No. 4 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
690,825		88,574	9,908	376,391

Proposal No. 5: To approve the amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect, at the discretion of the Company's board of directors, a reverse stock split of all of the outstanding shares of its Common Stock at a ratio in the range of 1-for-2 to 1-for-100. Proposal No. 5 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
984,342		162,507	18,849	0

Proposal No. 6: To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos 1, 2, 3, 4, and/or 5. Proposal No. 6 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
991,353		136,304	38,041	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CATHETER PRECISION, INC.



Date:	April 15, 2026	By:	/s/ Philip Anderson
			Philip Anderson
			Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Catheter Precision (VTAK) disclose in this 8-K filing?

Catheter Precision disclosed the results of a Special Meeting of stockholders held on April 15, 2026. The company reported quorum details and detailed vote counts for six proposals described in its definitive proxy statement filed on March 23, 2026.

How many Catheter Precision (VTAK) shares were outstanding and represented at the meeting?

The company reported 2,357,127 shares of common stock outstanding as of March 9, 2026. At the Special Meeting, 1,165,698 shares were represented in person or by proxy, amounting to approximately 49.5% of the outstanding common shares entitled to vote.

How many proposals did Catheter Precision (VTAK) stockholders consider?

Stockholders considered six proposals at the Special Meeting. These proposals are described in detail in Catheter Precision’s definitive proxy statement on Schedule 14A, which was filed with the Securities and Exchange Commission on March 23, 2026 before the meeting.

What were some of the vote totals reported by Catheter Precision (VTAK)?

The company reported proposal-level vote tallies, such as 690,693 votes for, 85,706 against, 9,908 abstentions, and 379,391 broker non-votes on one item, and 991,353 for, 136,304 against, and 38,041 abstentions with no broker non-votes on another item.

Where can investors find full details of the Catheter Precision (VTAK) proposals?

The six proposals voted on at the Special Meeting are described in Catheter Precision’s definitive proxy statement on Schedule 14A. That proxy statement was filed with the Securities and Exchange Commission on March 23, 2026 and provides full narrative detail on each proposal.

Filing Exhibits & Attachments

4 documents